In this renewal application we designed experiments aimed to capitalize on two major advances which occurred during the last funding period; 1. HGF biology: Hepatocyte Growth Factor (HGF) is now fully cloned and sequenced, in part from work funded by this grant in its earlier periods. Its receptor (encoded by the proto-oncogene c-met) is now well characterized. Activation of HGF by urokinase is now well documented. 2. In its new location in the university of Pittsburgh the lab has now access to hepatic tissue from the largest liver transplantation program in the world. Approximately 450 cases of liver at end stages of disease is available annually. The lab has now access to an existing collection of frozen tissue and paraffin blocks from hundreds of well defined stages of human hepatic disease. It also has access to all the new livers resected from transplantation cases. The project is now focusing on utilizing the new knowledge on HGF biology and the access of human liver tissues to focus on two lethal forms of human liver disease where growth disregulation leads to death: A. Hepatocellular Carcinoma (HCC). This is the most frequent cancer in the world. HGF is mitogenic and motogenic in normal human hepatocytes but is only motogenic and sometimes mitoinhibitory in human hepatocellular carcinomas. We will examine the role of HGF as a mitogen, motogen and mitoinhibitor in the evolution of human hepatocellular carcinoma from its earliest stages (atypical adenomatous hyperplasia, (AAH) seen as solitary nodules in cirrhosis), to its most advanced widely invasive forms. The role of HGF activation by urokinase in the evolution of this disease will be also examined. The potential mitoinhibitory effects of HGF on HCC, if properly documented understood, may have a therapeutic potential in this disease. B. Fulminant liver Failure (FHF): In this condition, hepatocyte regeneration ceases, stem cell compartment (ductular hepatocytes) becomes activated, solitary clonal growths of hepatocytes (pseudoadenomas) grow to a hugh size. HGF levels in the plasma are extremely high. We will investigate; a. the role of HGF as a mitogen, motogen and morphogen in the evolution of new cell populations in this disease; b. the role of high doses of HGF in the inhibition of hepatocyte regeneration (leading to death of the patient); c. the effect of high doses of HGF in the activation of the stem cell compartment in the human liver.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA030241-19
Application #
2712556
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Freeman, Colette S
Project Start
1981-08-15
Project End
1999-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
19
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kang, Liang-I; Isse, Kumiko; Koral, Kelly et al. (2015) Tissue-type plasminogen activator suppresses activated stellate cells through low-density lipoprotein receptor-related protein 1. Lab Invest 95:1117-29
Lin, Chih-Wen; Mars, Wendy M; Paranjpe, Shirish et al. (2011) Hepatocyte proliferation and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 transgenic mice. Hepatology 54:620-30
Donthamsetty, Shashikiran; Bhave, Vishakha S; Kliment, Corrine S et al. (2011) Excessive hepatomegaly of mice with hepatocyte-targeted elimination of integrin linked kinase following treatment with 1,4-bis [2-(3,5-dichaloropyridyloxy)] benzene. Hepatology 53:587-95
Liu, Bowen; Bell, Aaron W; Paranjpe, Shirish et al. (2010) Suppression of liver regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice. Hepatology 52:1060-7
Apte, Udayan; Gkretsi, Vasiliki; Bowen, William C et al. (2009) Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology 50:844-51
Liu, Bowen; Paranjpe, Shirish; Bowen, William C et al. (2009) Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation. Am J Pathol 175:717-24
Gkretsi, Vasiliki; Apte, Udayan; Mars, Wendy M et al. (2008) Liver-specific ablation of integrin-linked kinase in mice results in abnormal histology, enhanced cell proliferation, and hepatomegaly. Hepatology 48:1932-41
Limaye, Pallavi B; Alarcon, Gabriela; Walls, Andrew L et al. (2008) Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest 88:865-72
Limaye, Pallavi B; Bowen, William C; Orr, Anne V et al. (2008) Mechanisms of hepatocyte growth factor-mediated and epidermal growth factor-mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. Hepatology 47:1702-13
Gkretsi, Vasiliki; Bowen, William C; Yang, Yu et al. (2007) Integrin-linked kinase is involved in matrix-induced hepatocyte differentiation. Biochem Biophys Res Commun 353:638-43

Showing the most recent 10 out of 100 publications